Revised Guide Clarifies Scope Of EMA Policy On Proactive Publication Of Clinical Data
Executive Summary
The European Medicines Agency has issued revised guidance to further clarify what information in regulatory submissions is covered by its policy on the proactive publication of clinical data. The updated guideline also addresses certain procedural issues to help companies submit proposed redactions.
You may also be interested in...
It’s Started: EMA Proactively Publishes Clinical Data On New Drugs
The European Medicines Agency has delivered on its promise to grant public access to clinical reports that form the basis of its recommendations to the European Commission on whether or not a medicine should be authorized for use in the EU.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.